Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIND Nanotherapy Shows Early Cancer Efficacy In The Clinic

This article was originally published in The Pink Sheet Daily

Executive Summary

Strong preclinical data for BIND-014, docetaxel-carrying particles engineered using BIND’s Accurin platform, translated into positive results against tumors not usually vulnerable to the cancer drug, the company reported at a late-breaker poster session of the American Association for Cancer Research annual meeting.

You may also be interested in...



Bind Lands Nanoparticle Development Deal With Pfizer

The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.

Stealth Ninja Nanoparticle Increases Uptake Of Imaging Agents And Drugs

Researchers have devised a tiny synthetic peptide that signals macrophages scavenging for foreign invaders in the body to ignore it and move on. The molecule can be attached to imaging agents, drugs, and biologics, increasing their uptake by shielding them from attack by the immune system.

Deals Of The Week: Shire/arGEN-X/Ethris, Evotec/Yale, Amgen/Bind Biosciences

GSK’s venture arm outlines its investment priorities, which involve changes to the biopharma business model.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel